BCTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
BriaCell Therapeutics's Total Stockholders Equity for the quarter that ended in Jan. 2024 was $-8.07 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. BriaCell Therapeutics's Book Value per Share for the quarter that ended in Jan. 2024 was $-0.51. The ratio of a company's debt over equity can be used to measure how leveraged this company is. BriaCell Therapeutics's Debt-to-Equity for the quarter that ended in Jan. 2024 was 0.00.
The historical data trend for BriaCell Therapeutics's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BriaCell Therapeutics Annual Data | |||||||||||||||||||||
Trend | Jul14 | Jul15 | Jul16 | Jul17 | Jul18 | Jul19 | Jul20 | Jul21 | Jul22 | Jul23 | |||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | -0.69 | -3.60 | 27.67 | 10.33 | -3.78 |
BriaCell Therapeutics Quarterly Data | ||||||||||||||||||||
Apr19 | Jul19 | Oct19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Total Stockholders Equity | Get a 7-Day Free Trial | -1.28 | -5.89 | -3.78 | 2.72 | -8.07 |
BriaCell Therapeutics (NAS:BCTX) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
BriaCell Therapeutics's Book Value per Share for the quarter that ended in Jan. 2024 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (-8.073 | - | 0) | / | 15.9817 | |
= | -0.51 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
BriaCell Therapeutics's Debt-to-Equity for the quarter that ended in Jan. 2024 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (0 | + | 0) | / | -8.073 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of BriaCell Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Jamieson Bondarenko | director | 402-1 SCOTT ST.`, TORONTO A6 M5E 1A1 |
Jane A Gross | director | 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121 |
Rebecca Taub | director | 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Gadi Levin | officer: CFO & Secretary | MOSHAV AZRIEL 108, LEV HASHARON L3 4582500 |
Priore Giuseppe Del | officer: Chief Medical Officer | 44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005 |
Williams V. Williams | director, officer: President & CEO | 620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083 |
Martin E. Schmieg | director | 201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103 |
Miguel A. Lopez-lago | officer: Chief Scientific Officer | 2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130 |
Vaughn C. Embro-pantalony | director | P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0 |
Marc Lustig | director | 4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3 |
From GuruFocus
By sperokesalga sperokesalga • 05-15-2023
By Marketwired • 08-31-2023
By sperokesalga sperokesalga • 02-10-2023
By Stock market mentor Stock market mentor • 01-23-2023
By Value_Insider Value_Insider • 11-15-2022
By Stock market mentor Stock market mentor • 01-18-2023
By Value_Insider Value_Insider • 12-08-2022
By Value_Insider Value_Insider • 11-10-2022
By Marketwired • 10-11-2023
By Marketwired • 10-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.